Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Supplemental Cash Flow Information (Tables)

12 Months Ended

Dec. 31, 2020

	For The Years Ended December 31,
	2020		2019
Net cash used in operating activities of discontinued operations	$	-	$	(30	)

Net cash provided by investing activities of discontinued operations	$	-	$	-

Supplemental Disclosure of Other Cash Flow Information

(in thousands)

Cash paid for taxes		$	218			$	227
Cash paid for interest		$	60			$	170

Supplemental Disclosures of Non Cash Activities

(in thousands)

	Years Ended
	December 31,
	2020		2019
Operating
Adoption of ASC 842 - right of use asset	$	-	$	2,449
Adoption of ASC 842 - operating lease liability	$	-	$	2,536

Investing
Preferred Stock Deemed Dividend	$	3,033	$	-
Financing

Accrued financing costs	$	31	$	342
Accrued preferred dividends	$	-	$	429